Article Details
Retrieved on: 2024-08-09 12:25:50
Tags for this article:
Click the tags to see associated articles and topics
Excerpt
Truist Securities has adjusted its price target for Exelixis (NASDAQ: NASDAQ:EXEL), a biotechnology company, raising it to $33 from $32 as the ...
Article found on: www.investing.com
This article is found inside other hiswai user's workspaces. To start your own collection, sign up for free.
Sign UpAlready have an account? Log in here